Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.48 |
| ▸ | FEN1 | P39748 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29171625 | 0.91 | NPC1 (0.56) | GSK3BHRH3MAPT | |
| Hydrochloric Acid SCHEMBL11095307 | 0.86 | GSK3B (0.46) | GSK3BSIGMAR1HRH3KDM4E | |
| SCHEMBL7358604 | 0.86 | SIGMAR1 (0.74) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL5321242 | 0.84 | MEN1 (0.51) | GSK3BSIGMAR1DRD2HTR2AHTR2C | |
| SCHEMBL15536848 | 0.84 | MAPT (0.50) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11095799 | 0.82 | ALDH1A1 (0.55) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL17141124 | 0.82 | SIGMAR1 (0.53) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL5454981 | 0.81 | HTR3E (0.46) | GSK3BHRH3ERCC5FEN1KDM4E | |
| SCHEMBL5454976 | 0.81 | HTR3E (0.46) | GSK3BHRH3ERCC5FEN1KDM4E | |
| SCHEMBL5469826 | 0.80 | DRD2 (0.73) | SIGMAR1DRD2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111472056-B | Purifying CO in waste gas2Adsorption film, preparation method and regeneration method | 上海凯矜新材料科技有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-107721834-B | Preparation method of 1- (4-chlorphenyl) -2-cyclopropyl-1-acetone | 青岛润农化工有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-111472056-A | Purifying CO in waste gas2Adsorption film, preparation method and regeneration method | 成都其其小数科技有限公司 | 2020-07-31 | — | — | CN | disclosed |
| WO-2017031325-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017031325-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
| EP-2440535-A1 | ANTIFUNGAL 1,2,4-TRIAZOLYL DERIVATIVES HAVING A 5- SULFUR SUBSTITUENT | BASF SE (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20120077676-A1 | Antifungal 1,2,4-Triazolyl Derivatives Having a 5-Sulfur Substituent | BASF SE (DE) | 2012-03-29 | — | — | US | disclosed |
| WO-2010142779-A1 | ANTIFUNGAL 1,2,4-TRIAZOLYL DERIVATIVES HAVING A 5- SULFUR SUBSTITUENT | BASF SE (DE) | 2010-12-16 | — | — | WO | disclosed |
| US-5770741-A | FUNGICIDE INTERMEDIATE | SANDOZ LTD. (CH) | 1998-06-23 | — | — | US | disclosed |
| EP-0321409-B1 | CYCLOPROPANE DERIVATIVES | SANDOZ AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| US-4973767-A | SUBSTITUTED ETHANOLS, CHEMICAL INTERMEDIATES FOR FUNGICIDES | SANDOZ LTD. (CH) | 1990-11-27 | — | — | US | disclosed |
| US-4849439-A | α-phenyl-α-cyclopropylalkyene-1H-imidazole- and 1,2,4 triazole-ethanols as antimycotic agents | SANDOZ LTD. (CH) | 1989-07-18 | — | — | US | disclosed |
| EP-0321409-A2 | Cyclopropane derivatives | SANDOZ AG (CH) | 1989-06-21 | — | — | EP | disclosed |
| US-4664696-A | PHYTOPATHOGENS | SANDOZ LTD. (CH) | 1987-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077676-A1 | Antifungal 1,2,4-Triazolyl Derivatives Having a 5-Sulfur Substituent | ERG28, STS, CYP51A1 | GSK3B 2253/4885SIGMAR1 3020/4885DRD2 1848/4885 |
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | GSK3B 242/4885SIGMAR1 588/4885DRD2 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.